Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2016

01-08-2016 | Review

Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide

Authors: Saad Ghaus, Helmut Neumann, Humayun Muhammad, Gian Eugenio Tontini, Sauid Ishaq

Published in: Digestive Diseases and Sciences | Issue 8/2016

Login to get access

Abstract

Background

Barrett’s esophagus is a premalignant condition of the esophagus leading to esophageal adenocarcinoma. No consensus exists between the UK and USA concerning the diagnosis of Barrett’s esophagus. Although the diagnostic procedure is common, the required findings and diagnostic criteria vary. Both guidelines require endoscopy showing columnar epithelia lining the esophagus, but the US guidelines require the additional finding of intestinal metaplasia on biopsy to confirm diagnosis. Achievement of a consensus is of particular importance due to the established progression from Barrett’s esophagus to esophageal adenocarcinoma. Of further importance is the increasing incidence of esophageal adenocarcinoma, a condition with poor overall survival, leading to various opinions on the utility of surveillance in patients.

Discussion

A review of the vast array of literature revealed that substantial evidence exists in favor of both diagnostic criteria; hence, there is no easy way to identify the “correct” method of diagnosing Barrett’s esophagus. USA recommends surveillance of Barrett’s esophagus, whereas UK does not advocate it unless dysplasia is present. Surveillance was found to be effective, but this varied as did cost-effectiveness.

Summary

Further research into diagnostic methods for Barrett’s esophagus is needed to address areas of limited understanding, such that agreement can be reached and practice standardized. Surveillance was generally advocated, but with different criteria and time intervals, and new methods are being evaluated.
Literature
2.
go back to reference Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefPubMed Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefPubMed
4.
go back to reference Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur. J. Epidemiol. 2011;26:739–745.CrossRefPubMed Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur. J. Epidemiol. 2011;26:739–745.CrossRefPubMed
5.
go back to reference Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.CrossRefPubMed Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.CrossRefPubMed
6.
go back to reference Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefPubMed Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefPubMed
7.
go back to reference Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 2002;11:235–256.CrossRefPubMed Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 2002;11:235–256.CrossRefPubMed
8.
go back to reference Aida J, Vieth M, Shepherd N, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? Am. J. Surg. Pathol. 2015;39:188–196.CrossRefPubMed Aida J, Vieth M, Shepherd N, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? Am. J. Surg. Pathol. 2015;39:188–196.CrossRefPubMed
9.
go back to reference Alvarez Herrero L, Curvers W, van Vilsteren F, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45:876–882.CrossRefPubMed Alvarez Herrero L, Curvers W, van Vilsteren F, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45:876–882.CrossRefPubMed
10.
go back to reference Armstrong D. Review article: towards consistency in the endoscopic diagnosis of barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20:40–47.CrossRefPubMed Armstrong D. Review article: towards consistency in the endoscopic diagnosis of barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20:40–47.CrossRefPubMed
11.
go back to reference Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145–150.CrossRef Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145–150.CrossRef
12.
go back to reference American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef
13.
go back to reference Repaka A, Chak A. Endoscopic management of Barrett esophagus. Nat. Rev. Gastroenterol. Hepatol. 2011;8:582–591.CrossRefPubMed Repaka A, Chak A. Endoscopic management of Barrett esophagus. Nat. Rev. Gastroenterol. Hepatol. 2011;8:582–591.CrossRefPubMed
14.
go back to reference Sharma P, Brill J, Canto M, et al. White Paper AGA: advanced imaging in Barrett’s Esophagus. Clin. Gastroenterol. Hepatol. 2015;13:2209–2218.CrossRefPubMed Sharma P, Brill J, Canto M, et al. White Paper AGA: advanced imaging in Barrett’s Esophagus. Clin. Gastroenterol. Hepatol. 2015;13:2209–2218.CrossRefPubMed
15.
go back to reference Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N. Engl. J. Med. 1976;295:476–480.CrossRefPubMed Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N. Engl. J. Med. 1976;295:476–480.CrossRefPubMed
16.
go back to reference Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009;104:816–824.CrossRefPubMedPubMedCentral Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009;104:816–824.CrossRefPubMedPubMedCentral
17.
go back to reference Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Archiv. 2003;443:597–601. doi:10.1038/ajg.2015.116.CrossRefPubMed Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Archiv. 2003;443:597–601. doi:10.​1038/​ajg.​2015.​116.CrossRefPubMed
18.
go back to reference Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010;105:1523–1530.CrossRefPubMed Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010;105:1523–1530.CrossRefPubMed
19.
go back to reference Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 1996;44:91–95.CrossRefPubMed Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 1996;44:91–95.CrossRefPubMed
20.
go back to reference Shaheen N, Falk G, Iyer P, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016;111:30–50.CrossRefPubMed Shaheen N, Falk G, Iyer P, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016;111:30–50.CrossRefPubMed
21.
go back to reference Fitzgerald R, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed Fitzgerald R, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
22.
go back to reference Khandwalla H, Graham D, Kramer J, et al. Corrigendum: Barrett’s Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am. J. Gastroenterol. 2014;109:1123.CrossRef Khandwalla H, Graham D, Kramer J, et al. Corrigendum: Barrett’s Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am. J. Gastroenterol. 2014;109:1123.CrossRef
23.
go back to reference Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007;102:1154–1161.CrossRefPubMed Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007;102:1154–1161.CrossRefPubMed
24.
go back to reference Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007;42:1271–1274.CrossRefPubMed Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007;42:1271–1274.CrossRefPubMed
25.
go back to reference Chandrasoma P. Diagnostic atlas of gastroesophageal reflux disease. Amsterdam: Elsevier/Academic Press; 2007. Chandrasoma P. Diagnostic atlas of gastroesophageal reflux disease. Amsterdam: Elsevier/Academic Press; 2007.
26.
go back to reference Rothstein F, Dahms B. Barrett’s esophagus in children. In: Spechler SJ, Goyal R, eds. Barrett’s Esophagus: pathophysiology, diagnosis, and management. New York: Elseiver; 1985. Rothstein F, Dahms B. Barrett’s esophagus in children. In: Spechler SJ, Goyal R, eds. Barrett’s Esophagus: pathophysiology, diagnosis, and management. New York: Elseiver; 1985.
27.
go back to reference Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984;8:563–573.CrossRefPubMed Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984;8:563–573.CrossRefPubMed
28.
go back to reference Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—Is intestinal metaplasia dead? Am. J. Gastroenterol. 2009;104:2588–2594.CrossRefPubMed Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—Is intestinal metaplasia dead? Am. J. Gastroenterol. 2009;104:2588–2594.CrossRefPubMed
29.
go back to reference Gatenby PAC, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non dysplastic columnar lined esophagus. Scand. J. Gastroenterol. 2008;43:524–530.CrossRefPubMed Gatenby PAC, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non dysplastic columnar lined esophagus. Scand. J. Gastroenterol. 2008;43:524–530.CrossRefPubMed
30.
go back to reference Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed
31.
go back to reference Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester TR. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus. 2007;20:36–41.CrossRefPubMed Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester TR. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus. 2007;20:36–41.CrossRefPubMed
32.
go back to reference Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012;36:1–7.CrossRefPubMed Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012;36:1–7.CrossRefPubMed
33.
go back to reference Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.CrossRefPubMed Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.CrossRefPubMed
34.
go back to reference Kariv R, Plesec T, Goldblum J, et al. The seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009;7:653–658.CrossRefPubMed Kariv R, Plesec T, Goldblum J, et al. The seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009;7:653–658.CrossRefPubMed
35.
go back to reference Ishaq S, Harper E, Brown J. Survey of current clinical practice in the diagnosis, management and surveillance of Barrett’s metaplasia: a UK national survey. Gut. 2003;53:A32. Ishaq S, Harper E, Brown J. Survey of current clinical practice in the diagnosis, management and surveillance of Barrett’s metaplasia: a UK national survey. Gut. 2003;53:A32.
36.
go back to reference Das D, Ishaq S, Harrison R, et al. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008;103:1079–1089.CrossRefPubMed Das D, Ishaq S, Harrison R, et al. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008;103:1079–1089.CrossRefPubMed
37.
go back to reference Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009;7:736–742.CrossRefPubMedPubMedCentral Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009;7:736–742.CrossRefPubMedPubMedCentral
38.
go back to reference Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am. J. Gastroenterol. 2015;110:662–682.CrossRefPubMedPubMedCentral Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am. J. Gastroenterol. 2015;110:662–682.CrossRefPubMedPubMedCentral
39.
go back to reference Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001;36:445–456.CrossRefPubMed Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001;36:445–456.CrossRefPubMed
40.
go back to reference Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed
41.
go back to reference Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment. Pharmacol. Ther. 2008;27:316–320.CrossRefPubMed Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment. Pharmacol. Ther. 2008;27:316–320.CrossRefPubMed
42.
go back to reference Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1.CrossRefPubMed Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1.CrossRefPubMed
43.
go back to reference Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 2004;91:997–1003.CrossRefPubMed Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 2004;91:997–1003.CrossRefPubMed
44.
go back to reference Sonnenberg A, Soni A, Sampliner R. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002;16:41–50.CrossRefPubMed Sonnenberg A, Soni A, Sampliner R. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002;16:41–50.CrossRefPubMed
45.
go back to reference Kastelein F, van Olphen S, Steyerberg E, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2014;64:864–871.CrossRefPubMed Kastelein F, van Olphen S, Steyerberg E, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2014;64:864–871.CrossRefPubMed
46.
go back to reference Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of undergoing surveillance for Barrett’s oesophagus: observational study. BMJ. 2000;321:1252–1255.CrossRefPubMedPubMedCentral Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of undergoing surveillance for Barrett’s oesophagus: observational study. BMJ. 2000;321:1252–1255.CrossRefPubMedPubMedCentral
47.
go back to reference Corley D, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss N. Impact of endoscopic surveillance on mortality from Barrett’s Esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.e1.CrossRefPubMedPubMedCentral Corley D, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss N. Impact of endoscopic surveillance on mortality from Barrett’s Esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.e1.CrossRefPubMedPubMedCentral
48.
go back to reference Bhat S, Coleman H, Yousef F, et al. Risk of malignant progression in Barrett’s Esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral Bhat S, Coleman H, Yousef F, et al. Risk of malignant progression in Barrett’s Esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral
49.
go back to reference Cooper SC, El-agib A, Dar S, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur. J. Gastroenterol. Hepatol. 2009;21:850–854.CrossRefPubMed Cooper SC, El-agib A, Dar S, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur. J. Gastroenterol. Hepatol. 2009;21:850–854.CrossRefPubMed
Metadata
Title
Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide
Authors
Saad Ghaus
Helmut Neumann
Humayun Muhammad
Gian Eugenio Tontini
Sauid Ishaq
Publication date
01-08-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4138-x

Other articles of this Issue 8/2016

Digestive Diseases and Sciences 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.